Shares of Zoetis Inc. dropped sharply in morning trading, sliding -20.95% to $87.92 and establishing a new 52-week low after the company posted first-quarter results that fell short of Wall Street projections and revised its outlook for the year.
For Q1 2026, Zoetis reported sales of $2.26 billion, a year-on-year increase of 1.9% that nonetheless missed analysts' expectations. On the profit line, non-GAAP earnings per share came in at $1.53, which the company said was 5.3% below consensus forecasts. In response to the weaker start to the year, management pulled down its full-year adjusted EPS guidance to $6.93 at the midpoint and trimmed revenue guidance to $9.82 billion at the midpoint, down from a prior midpoint of $9.93 billion.
Company leadership attributed the deterioration primarily to conditions in the U.S. market. CEO Kristin Peck said that "pet owners demonstrated increased price sensitivity, resulting in a decline in veterinary visits and softer demand for premium innovative products," and added that "competition intensified across key pet care categories, including dermatology and parasiticides." The U.S. segment was a notable drag, with revenue down 8% and companion animal product sales falling 11% amid softer end-market demand and a more competitive landscape.
The profit picture was further weakened by a sizable contraction in operating performance. Zoetis logged an adjusted operating margin of 33.5%, a decrease of 6.4 percentage points from the same period a year earlier. That margin compression contributed to investor unease and amplified the market reaction.
Insider activity added to the negative tone surrounding the shares. Data cited by the company show no insider purchases and two insider sales in the past six months. Among those transactions, CEO Kristin Peck sold 20,000 shares for an estimated $2.54 million.
The equity market at large offered little shelter for Zoetis on the trading day. The S&P 500 gained just +0.03%, the Dow Jones Industrial Average rose +0.16%, and the NASDAQ was up +0.19%, indicating that the stock's decline was overwhelmingly company-specific rather than a reflection of broader market weakness.
Analysts and investors responded quickly to the unexpected combination of missed targets and reduced guidance. UBS had already cut its price target on Zoetis from $136 to $130 on April 28, while keeping a Neutral rating and noting a cautious outlook for Q1 amid softer demand trends. The more recent results and guidance cut have prompted further reassessment of valuation and what market participants are willing to pay for the shares.
Market observers pointed to several intersecting issues that pressured sentiment: a rare double miss on both revenue and earnings, a guidance reduction that landed below consensus, sharp margin deterioration, and an apparent erosion of pricing power within the core U.S. companion animal market. The update also raised concerns about margin pressure tied to recent acquisitions, and intensified worries that profitability could remain constrained for longer than investors had anticipated.
As trading continued, the shares extended a recent string of losses and carved out fresh 52-week lows, reflecting a broader reset in valuations across the animal health sector. Given the combination of weak top- and bottom-line performance, lower guidance, and contracting margins, investors are reassessing the company's near-term prospects and the valuation they assign to Zoetis.
Clear summary
Zoetis missed Q1 revenue and non-GAAP EPS expectations, reduced full-year adjusted EPS and revenue guidance, reported an 8% decline in U.S. revenue and an 11% drop in companion animal sales, and saw adjusted operating margin fall to 33.5%. The stock plunged -20.95% to $87.92, marking a new 52-week low, while insider sales and an already cautious analyst stance added to investor pressure.